Search results
Results from the WOW.Com Content Network
Prior to the IPO, it had $62 million in cash and equivalents on its balance sheet. The IPO raised approximately $167 million. So, it should now have around $229 million in cash, a little over four ...
This year has seen more than its share of successful IPOs – and some giant flops. The extremes should have been expected, in a year with a record number of new public offerings. The second ...
(Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up pace. The ...
These biotech stocks jumped 31% or more over the last few days. Can their momentum continue? Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ...
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure ...
Intersect ENT develops products for Ear, Nose and Throat conditions as well as the treatment of sinusitis. [2] Its most known device is the Propel mometasone furoate implant that is used after sinus surgery to keep the sinus passageways open and aid in the healing process by delivering an anti-inflammatory steroid directly to the sinuses.
Another busy week of IPOs is set for the week of Sept. 28. Here is a look at many of the companies set to price and go public this week.Boqii Holdings Ltd.The largest pet-focused platform by ...
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]